Skip to Main Content
Table 3.

Nutritional/functional, laboratory, and quality of life variables evaluated after 1, 2, and 4 months of treatment on 39 patients

VariablesBaseline1 moP2 moP4 moP
Body weight (kg) 55.1 ± 10 56.5 ± 10.5 0.001 56.4 ± 9.7 0.036 57 ± 9.8 0.031 
LBM (kg) 38 ± 9 38.9 ± 9 0.059 39.4 ± 8.9 0.045 39.7 ± 8.7 0.024 
Grip strength (kg) 28.0 ± 10.4 27.8 ± 9.5 0.879 27.9 ± 9.3 0.673 28.1 ± 9.5 0.827 
Appetite 5.5 ± 2.5 6.6 ± 2.2 0.005 6.8 ± 1.9 0.001 7.0 ± 1.6 0.004 
IL-6 (pg/mL) 12.5 ± 9.9 8.8 ± 8.7 0.002 7.5 ± 8.6 0.003 7.4 ± 8.5 0.007 
TNF-α (pg/mL) 22.2 ± 16.6 19.5 ± 16 0.204 15.8 ± 13 0.020 14 ± 11.7 0.015 
Leptin (ng/mL) 5.9 ± 6.1 8.9 ± 10.6 0.008 10.2 ± 13.3 0.031 13.6 ± 13.3 <0.001 
ROS (FORT U) 468.5 ± 97.2 436.6 ± 92.5 0.033 437.7 ± 89.6 0.087 444.1 ± 93.6 0.162 
GPx (units/L) 8,206.6 ± 2,322.3 8,339.3 ± 2,411.8 0.726 8,295.9 ± 2,314.1 0.848 8,849.2 ± 2,629 0.211 
Quality of life questionnaires        
    EORTC QLQ-C30 65.9 ± 16.3 72.4 ± 15.6 0.008 71.8 ± 14.6 0.020 70.9 ± 14.6 0.044 
    EQ-5Dindex 0.50 ± 0.4 0.58 ± 0.4 0.175 0.56 ± 0.4 0.340 0.59 ± 0.4 0.114 
    EQ-5DVAS 49.4 ± 21.4 58.9 ± 22.7 0.016 58.6 ± 20.6 0.015 58.7 ± 19.4 0.009 
    MSFI-SF 20.1 ± 22.1 14.4 ± 20.3 0.125 11.8 ± 17.2 0.022 10.8 ± 14.4 0.004 
VariablesBaseline1 moP2 moP4 moP
Body weight (kg) 55.1 ± 10 56.5 ± 10.5 0.001 56.4 ± 9.7 0.036 57 ± 9.8 0.031 
LBM (kg) 38 ± 9 38.9 ± 9 0.059 39.4 ± 8.9 0.045 39.7 ± 8.7 0.024 
Grip strength (kg) 28.0 ± 10.4 27.8 ± 9.5 0.879 27.9 ± 9.3 0.673 28.1 ± 9.5 0.827 
Appetite 5.5 ± 2.5 6.6 ± 2.2 0.005 6.8 ± 1.9 0.001 7.0 ± 1.6 0.004 
IL-6 (pg/mL) 12.5 ± 9.9 8.8 ± 8.7 0.002 7.5 ± 8.6 0.003 7.4 ± 8.5 0.007 
TNF-α (pg/mL) 22.2 ± 16.6 19.5 ± 16 0.204 15.8 ± 13 0.020 14 ± 11.7 0.015 
Leptin (ng/mL) 5.9 ± 6.1 8.9 ± 10.6 0.008 10.2 ± 13.3 0.031 13.6 ± 13.3 <0.001 
ROS (FORT U) 468.5 ± 97.2 436.6 ± 92.5 0.033 437.7 ± 89.6 0.087 444.1 ± 93.6 0.162 
GPx (units/L) 8,206.6 ± 2,322.3 8,339.3 ± 2,411.8 0.726 8,295.9 ± 2,314.1 0.848 8,849.2 ± 2,629 0.211 
Quality of life questionnaires        
    EORTC QLQ-C30 65.9 ± 16.3 72.4 ± 15.6 0.008 71.8 ± 14.6 0.020 70.9 ± 14.6 0.044 
    EQ-5Dindex 0.50 ± 0.4 0.58 ± 0.4 0.175 0.56 ± 0.4 0.340 0.59 ± 0.4 0.114 
    EQ-5DVAS 49.4 ± 21.4 58.9 ± 22.7 0.016 58.6 ± 20.6 0.015 58.7 ± 19.4 0.009 
    MSFI-SF 20.1 ± 22.1 14.4 ± 20.3 0.125 11.8 ± 17.2 0.022 10.8 ± 14.4 0.004 

NOTE: Data are reported as mean ± SD. As for EORTC QLQ-C30, EQ-5D index, and EQ-5DVAS, the increasing of score corresponds to improvement of quality of life, whereas for MSFI-SF, the decrease of quality of life score corresponds to amelioration of fatigue. Significance was considered for P < 0.05 as calculated with Student's t test for paired data (posttreatment values versus baseline values). Significance for IL-6, TNF-α, and leptin was calculated using Wilcoxon ranks test.

Abbreviations: GPx, glutathione peroxidase; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer QLQ-C30; EQ-5D, Euro QL-5D; MSFI-SF, multidimensional fatigue symptom inventory-short form.

Close Modal

or Create an Account

Close Modal
Close Modal